File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma

TitleSelective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma
Authors
KeywordsHaploidentical
Hematopoietic stem cell transplantation
Immunotherapy
Neuroblastoma
Relapse
Issue Date2018
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTR
Citation
Pediatric Transplantation, 2018, v. 22 n. 6, article no. e13240 How to Cite?
AbstractRelapsed/refractory NB carries a bleak outcome, warranting novel treatment options. HaploHSCT induces a graft-versus-NB effect via natural killer cell alloreactivity. Review of patients with relapsed/refractory NB who underwent haploHSCT with ex vivo T-cell depletion in our unit from 2013 through 2018. Ten patients were identified (male=5; median age at haploHSCT=6.45 y, range: 3.49-11.02 y). Indications were relapsed in 7 and refractoriness in 3; disease status at haploHSCT was CR in 2, PR in 6, and PD in 2. All patients received peripheral blood stem cell grafts after ex vivo T-cell depletion (CD3/CD19-depletion=1; TCR-αβ/CD19-depletion=4; CD3/CD45RA-depletion=4; and TCR-αβ/CD45RA-depletion=1). Conditioning regimens were fludarabine-based. Neutrophils engrafted on median D + 10 (range: D + 9 to +13), and platelets engrafted (≥20 × 109/L) on median D + 8 (range: D + 5 to D + 14). Early T-and NK-cell recovery were evident. Of the 10 patients, acute rejection developed in 1 (who died of PD despite rescue HSCT), and 1 died of sepsis before engraftment; 8 experienced full donor-chimerism post-HSCT. Among the 8, 6 experienced CR, 1 died of PD, and 1 died of pulmonary hypertensive crisis before evaluation. At publication, 4 were in remission (2.8, 7.4, 28.5, and 58.9 months). No significant GvHD occurred. HaploHSCT with selective ex vivo T-cell depletion may be a safe and useful salvage strategy for relapsed/refractory NB.
Persistent Identifierhttp://hdl.handle.net/10722/264250
ISSN
2017 Impact Factor: 1.377
2015 SCImago Journal Rankings: 0.542
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, APY-
dc.contributor.authorLee, PPW-
dc.contributor.authorKwok, JSY-
dc.contributor.authorLeung, RYY-
dc.contributor.authorChiang, AKS-
dc.contributor.authorHa, SY-
dc.contributor.authorCheuk, KLD-
dc.contributor.authorChan, GCF-
dc.date.accessioned2018-10-22T07:51:56Z-
dc.date.available2018-10-22T07:51:56Z-
dc.date.issued2018-
dc.identifier.citationPediatric Transplantation, 2018, v. 22 n. 6, article no. e13240-
dc.identifier.issn1397-3142-
dc.identifier.urihttp://hdl.handle.net/10722/264250-
dc.description.abstractRelapsed/refractory NB carries a bleak outcome, warranting novel treatment options. HaploHSCT induces a graft-versus-NB effect via natural killer cell alloreactivity. Review of patients with relapsed/refractory NB who underwent haploHSCT with ex vivo T-cell depletion in our unit from 2013 through 2018. Ten patients were identified (male=5; median age at haploHSCT=6.45 y, range: 3.49-11.02 y). Indications were relapsed in 7 and refractoriness in 3; disease status at haploHSCT was CR in 2, PR in 6, and PD in 2. All patients received peripheral blood stem cell grafts after ex vivo T-cell depletion (CD3/CD19-depletion=1; TCR-αβ/CD19-depletion=4; CD3/CD45RA-depletion=4; and TCR-αβ/CD45RA-depletion=1). Conditioning regimens were fludarabine-based. Neutrophils engrafted on median D + 10 (range: D + 9 to +13), and platelets engrafted (≥20 × 109/L) on median D + 8 (range: D + 5 to D + 14). Early T-and NK-cell recovery were evident. Of the 10 patients, acute rejection developed in 1 (who died of PD despite rescue HSCT), and 1 died of sepsis before engraftment; 8 experienced full donor-chimerism post-HSCT. Among the 8, 6 experienced CR, 1 died of PD, and 1 died of pulmonary hypertensive crisis before evaluation. At publication, 4 were in remission (2.8, 7.4, 28.5, and 58.9 months). No significant GvHD occurred. HaploHSCT with selective ex vivo T-cell depletion may be a safe and useful salvage strategy for relapsed/refractory NB.-
dc.languageeng-
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTR-
dc.relation.ispartofPediatric Transplantation-
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectHaploidentical-
dc.subjectHematopoietic stem cell transplantation-
dc.subjectImmunotherapy-
dc.subjectNeuroblastoma-
dc.subjectRelapse-
dc.titleSelective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma-
dc.typeArticle-
dc.identifier.emailLiu, APY: apyliu@hku.hk-
dc.identifier.emailLee, PPW: ppwlee@hku.hk-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.emailHa, SY: syha@hku.hk-
dc.identifier.emailCheuk, KLD: klcheuk@hkucc.hku.hk-
dc.identifier.emailChan, GCF: gcfchan@hku.hk-
dc.identifier.authorityLiu, APY=rp01357-
dc.identifier.authorityLee, PPW=rp00462-
dc.identifier.authorityChiang, AKS=rp00403-
dc.identifier.authorityChan, GCF=rp00431-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/petr.13240-
dc.identifier.pmid29921011-
dc.identifier.scopuseid_2-s2.0-85056608444-
dc.identifier.hkuros295008-
dc.identifier.volume22-
dc.identifier.issue6-
dc.identifier.spagearticle no. e13240-
dc.identifier.epagearticle no. e13240-
dc.identifier.isiWOS:000442223700010-
dc.publisher.placeDenmark-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats